CA2660814C - Promedicaments hydrosolubles charges positivement contenant des acides aryl- et heteroarylpropioniques et dotes d'une tres grande vitesse de penetration cutanee - Google Patents

Promedicaments hydrosolubles charges positivement contenant des acides aryl- et heteroarylpropioniques et dotes d'une tres grande vitesse de penetration cutanee Download PDF

Info

Publication number
CA2660814C
CA2660814C CA2660814A CA2660814A CA2660814C CA 2660814 C CA2660814 C CA 2660814C CA 2660814 A CA2660814 A CA 2660814A CA 2660814 A CA2660814 A CA 2660814A CA 2660814 C CA2660814 C CA 2660814C
Authority
CA
Canada
Prior art keywords
diethylaminoethyl
compound
acoh
methyl
negative ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2660814A
Other languages
English (en)
Other versions
CA2660814A1 (fr
Inventor
Chongxi Yu
Lina Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Techfields Biochem Co Ltd
Original Assignee
Techfields Biochem Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Techfields Biochem Co Ltd filed Critical Techfields Biochem Co Ltd
Publication of CA2660814A1 publication Critical patent/CA2660814A1/fr
Application granted granted Critical
Publication of CA2660814C publication Critical patent/CA2660814C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

De nouveaux promédicaments chargés positivement contenant des acides aryl- et hétéroarylpropioniques représentés par la formule générale (1) "Structure 1" et par la formule générale (2) "Structure 2" ont été mis au point et synthétisés. Les composés représentés par la formule générale (1) "Structure 1" et par la formule générale (2) "Structure 2" indiquées ci-dessus peuvent être préparés à partir de dérivés fonctionnels de naproxène, suprofène, acide .alpha.-méthyl-(p-chlorobenzoyl)-5-méthoxy-2-méthylindole 3-acétique, flurbiprofène, carprofène, pranoprofène, benoxaprofène, alminoprofène, acide tiaprofénique, pirprofène, zaltoprofène, bermoprofène, loxoprofène, indoprofène, fenclorac, oxaprozine, fenbufène, orpanoxine, kétorolac, clidanac et les composés apparentés, (par exemple les halogénures d'acides ou les anhydrides mixtes), par réaction avec des alcools, thiols, ou amines appropriés. Ces promédicaments renferment des groupes amino à charge positive qui non seulement augmentent de façon importante la solubilité de ces médicaments, mais encore se lient à la charge négative sur le groupe de tête phosphate de membrane et poussent le promédicament dans le cytosol. Les résultats suggèrent que les promédicaments se diffusent à travers la peau humaine de 100-130 fois plus vite que leurs médicaments parents. Pris par la voie orale, les naproxène, suprofène, acide .alpha.-méthyl-(p-chlorobenzoyl)-5-méthoxy-2-méthylindole 3-acétique, flurbiprofène, carprofène, pranoprofène, benoxaprofène, alminoprofène, acide tiaprofénique, pirprofène, zaltoprofène, bermoprofène, loxoprofène, indoprofène, fenclorac, oxaprozine, fenbufène, orpanoxine, kétorolac, clidanac, et composés apparentés atteignent le taux de plasma de pic en 2-4 heures. Pris par la voie transdermique, les promédicaments ne prennent qu'environ 40-50 minutes pour atteindre le taux de plasma de pic. Dans le plasma, plus de 90% desdits promédicaments peuvent reprendre leur forme de médicament en quelques minutes. Les promédicaments peuvent être utilisés médicalement pour traiter n'importe quelles conditions répondant à un traitement par analgésiques anti-inflammatoires non stéroïdiens NSAIA chez l'homme ou chez l'animal. Les promédicaments peuvent être administrés par voie orale autant que par voie transdermique dans toute thérapeutique et permettetn d'éviter la plupart des effets secondaires des NSAIA, plus particulièrement les troubles gastro-intestinaux tels que la dyspepsie, les saignements gastro-duodénaux, les ulcères gastriques et la gastrite. Les systèmes d'administration transdermique contrôlée des promédicaments permettent aux naproxène, suprofène, acide .alpha.-méthyl-(p-chlorobenzoyl)-5-méthoxy-2-methylindole 3-acétique, flurbiprofène, carprofène, pranoprofène, benoxaprofène, alminoprofène, acide tiaprofénique, pirprofène, zaltoprofène, bermoprofène, loxoprofène, indoprofène, fenclorac, oxaprozine, fenbufène, orpanoxine, kétorolac, clidanac et composés apparentés d'atteindre des taux thérapeutiques sanguins constants permettant d'optimiser l'efficacité et de réduire les effets secondaires des NSAIA. En outre, l'administration transdermique desdits promédicaments permet d'administrer la médication beaucoup plus facilement, notamment aux enfants.
CA2660814A 2006-08-15 2006-08-15 Promedicaments hydrosolubles charges positivement contenant des acides aryl- et heteroarylpropioniques et dotes d'une tres grande vitesse de penetration cutanee Active CA2660814C (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/052815 WO2008020270A1 (fr) 2006-08-15 2006-08-15 Promédicaments hydrosolubles chargés positivement contenant des acides aryl- et hétéroarylpropioniques et dotés d'une très grande vitesse de pénétration cutanée

Publications (2)

Publication Number Publication Date
CA2660814A1 CA2660814A1 (fr) 2008-02-21
CA2660814C true CA2660814C (fr) 2017-07-18

Family

ID=39081992

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2660814A Active CA2660814C (fr) 2006-08-15 2006-08-15 Promedicaments hydrosolubles charges positivement contenant des acides aryl- et heteroarylpropioniques et dotes d'une tres grande vitesse de penetration cutanee

Country Status (7)

Country Link
EP (1) EP2054384A4 (fr)
JP (1) JP5424880B2 (fr)
CN (1) CN101506161B (fr)
AU (1) AU2006347391B2 (fr)
CA (1) CA2660814C (fr)
HK (1) HK1137425A1 (fr)
WO (1) WO2008020270A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
PT2041068T (pt) * 2006-07-18 2017-02-17 Techfields Biochem Co Ltd Pró-fármacos solúveis em água positivamente carregados de ibuprofeno com taxa de penetração de pele muito rápida
JP5378219B2 (ja) 2006-10-02 2013-12-25 テックフィールズ バイオケム カンパニー リミテッド 非常に高い皮膚浸透率を有するプロスタグランジン及び関連化合物の正荷電水溶性プロドラッグ
AU2006350707A1 (en) 2006-11-08 2008-05-15 Chongxi Yu Transdermal delivery systems of peptides and related compounds
CA2671938C (fr) 2006-12-10 2017-10-17 Chongxi Yu Systemes d'administration transdermique de beta-lactamines
EP3181132A1 (fr) 2007-01-15 2017-06-21 Chongxi Yu Promédicaments positivement chargés solubles dans l'eau de rétinoïdes et de composés semblables à des rétinoïdes ayant des vitesses de pénétration dans la peau très élevées
PL2115140T3 (pl) 2007-01-31 2017-03-31 Yu Dodatnio naładowane rozpuszczalne w wodzie proleki 1H-imidazo[4,5-c]chinolino-4-amin i powiązane związki o bardzo wysokich wskaźnikach penetracji przez skórę
CN101687792B (zh) * 2007-06-04 2016-03-02 于崇曦 具有快速皮肤和生物膜穿透速度的非甾体抗炎药的前药及其医药用途
RU2630577C2 (ru) * 2008-12-04 2017-09-11 Чунси ЮЙ Композиции интенсивного проникновения и их применение
EP2427475B1 (fr) 2009-05-08 2020-11-04 Techfields Biochem Co., Ltd. Compositions promédicamenteuses à pénétration élevée de peptides et de composés apparentés à des peptides
US9969751B2 (en) 2009-06-10 2018-05-15 Techfields Pharma Co., Ltd. High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds
AU2013262320B2 (en) 2012-05-16 2018-02-22 Techfields Pharma Co., Ltd. High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions
CN105143174B (zh) * 2013-03-15 2021-01-12 苏州泰飞尔医药有限公司 治疗帕金森疾病的新型高穿透力药物及其药物组合物
JP5940036B2 (ja) * 2013-10-08 2016-06-29 テックフィールズ バイオケム カンパニー リミテッド 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ
US11242319B2 (en) 2014-11-05 2022-02-08 Flexus Biosciences, Inc. Immunoregulatory agents
US9862698B2 (en) 2014-12-16 2018-01-09 Adt Pharmaceuticals, Inc. Indenyl compounds, pharmaceutical compositions, and medical uses thereof
US20160168108A1 (en) 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
JP6290947B2 (ja) * 2016-02-05 2018-03-07 テックフィールズ バイオケム カンパニー リミテッド 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ
WO2019210223A1 (fr) 2018-04-26 2019-10-31 Adt Pharmaceuticals, Llc Indènes, indanes, azaindènes, azaindanes anticancéreux, compositions pharmaceutiques et utilisations
CN114746394B (zh) * 2020-09-09 2024-02-02 南京海融医药科技股份有限公司 一种芳基丙酸衍生物、药物组合物及其制备方法和应用
CN117916219A (zh) * 2021-07-06 2024-04-19 石家庄迪斯凯威医药科技有限公司 一类抗膀胱癌的季胺盐化合物及其应用
CN115850289B (zh) * 2021-09-24 2023-10-24 石家庄迪斯凯威医药科技有限公司 一种新型普拉洛芬衍生物及其药物组合物和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593024A (fr) * 1968-09-18 1970-05-25
CA1012159A (en) * 1972-06-27 1977-06-14 Michael Marx Dialkylaminoalkyl esters of 2-(6-methoxy-2-naphthyl) propionic acid and the pharmaceutically acceptable salts thereof
US3896145A (en) * 1972-07-24 1975-07-22 Hoffmann La Roche Carbazoles
ZA738203B (en) * 1972-10-24 1975-05-28 Janssen Pharmaceutica Nv Aroyl-substituted phenylacetic acid derivatives
JPS5826744B2 (ja) * 1975-12-24 1983-06-04 ヒサミツセイヤク カブシキガイシヤ シンキナプロピオンサン エステルユウドウタイノセイゾウホウ
IT1090782B (it) * 1977-11-30 1985-06-26 Menarini Sas 2 4 bifenilil 2 dietilamino alchil propionamide suoi sali e procedimenti di fabbricazione relativi
JPS58126846A (ja) * 1982-01-22 1983-07-28 Kaken Pharmaceut Co Ltd プロピオン酸アミノアルキルエステル誘導体、その製法およびそれを有効成分とする消炎、鎮痛剤
AU1508988A (en) * 1987-04-27 1988-10-27 Syntex Pharmaceuticals International Ltd. Omega-quaternary ammonium alkyl esters and thioesters of acidic nonsteroidal antiinflammatory drugs
IT1317826B1 (it) * 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
ITMI20010395A1 (it) * 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
ITMI20012025A1 (it) * 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono

Also Published As

Publication number Publication date
CN101506161B (zh) 2013-11-13
JP2010500989A (ja) 2010-01-14
JP5424880B2 (ja) 2014-02-26
AU2006347391A1 (en) 2008-02-21
CA2660814A1 (fr) 2008-02-21
HK1137425A1 (en) 2010-07-30
EP2054384A4 (fr) 2010-11-03
WO2008020270A1 (fr) 2008-02-21
EP2054384A1 (fr) 2009-05-06
CN101506161A (zh) 2009-08-12
AU2006347391B2 (en) 2013-03-07

Similar Documents

Publication Publication Date Title
CA2660814C (fr) Promedicaments hydrosolubles charges positivement contenant des acides aryl- et heteroarylpropioniques et dotes d'une tres grande vitesse de penetration cutanee
CA2658712C (fr) Promedicaments hydrosolubles a charge positive du diclofenac presentant une vitesse de penetration cutanee tres rapide
EP2623495B1 (fr) Promédicaments hydrosolubles positivement chargés d'acides N-arylanthraniliques à vitesse de pénétration cutanée très rapide
EP2049482B1 (fr) Promédicaments hydrosolubles chargés positivement d'acides aryl- et heteroarylacetiques avec une vitesse de pénétration de la peau très rapide
CA2657636C (fr) Promedicaments d'ibuprofene hydrosolubles charges positivement ayant un taux de penetration cutanee tres rapide
WO2008012603A1 (fr) Promédicaments hydrosolubles à charge positive du diflunisal et composés associés présentant une vitesse de pénétration cutanée très rapide
WO2008012605A1 (fr) Promédicaments hydrosolubles à charge positive de kétoprofène et composés associés à vitesse de pénétration cutanée très rapide
AU2013206218B2 (en) Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate
AU2013231152A1 (en) Positively charged water-soluble pro-drugs of ibuprofen
JP5940036B2 (ja) 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ
JP5629745B2 (ja) 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ
JP6290947B2 (ja) 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ
AU2018202140A1 (en) Positively charged water-soluble pro-drugs of ibuprofen

Legal Events

Date Code Title Description
EEER Examination request